{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:21:14Z","timestamp":1771935674094,"version":"3.50.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recombinant Vesicular Stomatitis Virus (rVSV) vector vaccines have become essential in combating emerging viral diseases and have shown promise in immunotherapy, particularly in the discipline of cancer treatment. Although extensive research has been conducted in this rVSV field, a comprehensive bibliometric and landscape analysis is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To depict the current research landscape of recombinant vaccines and antitumor agents based on the VSV vector, especially of the critical focus areas, emerging trends, and ongoing clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The software CiteSpace was used to conduct the bibliometric analysis to visualize rVSV research trends, prominent authors, leading institutions, contributing countries, frequently used keywords, and the top 10 most cited articles. Additionally, the advancements and research directions were explored by analyzing active clinical trials related to the rVSV field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 311 publications from 1996 to 2024 were screened out from the Web of Science Core Collection based on predefined inclusion criteria. The cumulative annual publication volume showed a steady increase, with the United States and Canada leading in research output. Notable authors such as Heinz Feldmann and John K. Rose were identified as the most frequently cited contributors. Key cluster and reference analyses revealed a shift from studying basic mechanisms to focusing on vaccine construction and clinical trials. Furthermore, efficient trials were identified in both infectious disease vaccines and antitumor agents, providing insights into potential applications in the indication expansion of currently applied vaccines and precise targeting strategies in newly developed tumor agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Benefited by the CiteSpace-generated bibliometric analysis, this study mapped the evolution of research and highlighted key topics in rVSV vaccine development. The comprehensive review of recent advancements and active clinical trials (using clinicaltrial.gov) offers valuable insights into current trends and future research directions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1711059","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:36:19Z","timestamp":1771223779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual role of rVSV vectors in prophylactic and therapeutic innovation: a comprehensive bibliometric and clinical trial perspective"],"prefix":"10.3389","volume":"17","author":[{"given":"Yueqing","family":"Chen","sequence":"first","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]},{"name":"Department of Microbiology, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxian","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Food Science and Nutritional Engineering, China Agricultural University","place":["Beijing, China"]},{"name":"Department of Population Health Science, Weill Cornell Medicine, Cornell University","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changwen","family":"Bie","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The Fourth Affiliated Hospital of Zhejiang University, School of Medicine","place":["Yiwu, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runze","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mijia","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4172\/2157-2526.S1-004","article-title":"Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of Filovirus infections","author":"Marzi","year":"2011","journal-title":"J Bioterror Biodef"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/bf01314961","article-title":"The glycoprotein G of rhabdoviruses","volume":"140","author":"Coll","year":"1995","journal-title":"Arch Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708955200","article-title":"Molecular architecture of the bipartite fusion loops of vesicular stomatitis virus glycoprotein G, a class iii viral fusion protein","volume":"283","author":"Sun","year":"2008","journal-title":"J Biol Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360713","article-title":"Antibodies to vesicular stomatitis virus proteins in patients with systemic lupus erythematosus and in normal subjects","volume":"36","author":"Hardgrave","year":"1993","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/v12090959","article-title":"Components and architecture of the rhabdovirus ribonucleoprotein complex","volume":"12","author":"Riedel","year":"2020","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"Rvsv\u03b4g-Zebov-Gp (Also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola zaire glycoprotein: standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"key":"B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/dna.2023.0368","article-title":"Oncolytic therapy of solid tumors by modified vesicular stomatitis virus","volume":"43","author":"Gao","year":"2024","journal-title":"DNA Cell Biol"},{"key":"B8","unstructured":"Matthews\n              T\n            \n          \n          Libguides: Web of Science Platform: Web of Science: Summary of Coveage: Clarivate\n          \n          2024"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.920813","article-title":"Emerging trends and new developments in regenerative medicine: A scientometric update (2000 - 2014)","volume":"14","author":"Chen","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1245719","article-title":"Trends in metabolic dysfunction in polycystic ovary syndrome: A bibliometric analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an Rvsv-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.646626","article-title":"Bibliometric analysis of global research trends on ultrasound microbubble: A quickly developing field","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00482-2","article-title":"An effective aids vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant Vsv-\u0394G-Spike vaccine provides protection against Sars-Cov-2 challenge","volume":"11","author":"Yahalom-Ronen","year":"2020","journal-title":"Nat Commun"},{"key":"B16","unstructured":"NeuroRx\n              IRP\n            \n          \n          Phase 2b\/3 Trial of Vsv-\u0394g Sars-Cov-2 Vaccine (Brilife) against Approved Comparator Vaccine\n          \n          2024"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.048","article-title":"Meeting report: Cepi consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12\u201313 February 2020","volume":"39","author":"Voss","year":"2021","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1225637","article-title":"Ebola vaccines in clinical trial: the promising candidates","volume":"13","author":"Wang","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the Vsv Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure treatment of Marburg virus infection","volume":"16","author":"Geisbert","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine Rvsv-Zebov","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0802","article-title":"Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses","volume":"18","author":"Goradel","year":"2022","journal-title":"Future Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.154","article-title":"Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus","volume":"17","author":"Bridle","year":"2009","journal-title":"Mol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against Sars-Cov-2-mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","article-title":"Neutralizing antibody and soluble Ace2 inhibition of a replication-competent Vsv-Sars-Cov-2 and a clinical isolate of Sars-Cov-2","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03276-13","article-title":"Vsv-Gp: A potent viral vaccine vector that boosts the immune response upon repeated applications","volume":"88","author":"Tober","year":"2014","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.050","article-title":"Heterologous prime\/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors","volume":"27","author":"Santra","year":"2009","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3201\/eid2104.142012","article-title":"Safety of recombinant Vsv-Ebola virus vaccine vector in pigs","volume":"21","author":"de Wit","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010658","article-title":"Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential","volume":"18","author":"Monath","year":"2022","journal-title":"PLoS Pathog"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PLoS Pathog"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.15.7642-7650.2002","article-title":"Adding genes to the Rna genome of vesicular stomatitis virus: positional effects on stability of expression","volume":"76","author":"Wertz","year":"2002","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.17.7895-7902.2000","article-title":"Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response","volume":"74","author":"Flanagan","year":"2000","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-006-0042-3","article-title":"Recombinant vesicular stomatitis virus as an Hiv-1 vaccine vector","volume":"28","author":"Clarke","year":"2006","journal-title":"Springer Semin Immunopathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1787981","article-title":"A tool with many applications: vesicular stomatitis virus in research and medicine","volume":"20","author":"Munis","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00794-11","article-title":"Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus","volume":"85","author":"Brown","year":"2011","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/v6020516","article-title":"Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters","volume":"6","author":"Prescott","year":"2014","journal-title":"Viruses"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094355","article-title":"Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates","volume":"9","author":"Mire","year":"2014","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B41","unstructured":"First Fda-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response\n          \n          \n          \n          2019"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105851","article-title":"Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo Ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines","volume":"225","author":"Felgner","year":"2024","journal-title":"Antiviral Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u03b4: first approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898631","article-title":"Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1988.39.312","article-title":"A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection","volume":"39","author":"Quiroz","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"B48","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/mto.2016.1","article-title":"Oncolytic vesicular stomatitis virus expressing interferon-\u0393 Has enhanced therapeutic activity","volume":"3","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.005","article-title":"Partners in crime: combining oncolytic viroimmunotherapy with other therapies","volume":"25","author":"Suzuki","year":"2017","journal-title":"Mol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-0600","article-title":"Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer","volume":"72","author":"Rommelfanger","year":"2012","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01643-19","article-title":"Experimental evolution generates novel oncolytic vesicular stomatitis viruses with improved replication in virus-resistant pancreatic cancer cells","volume":"94","author":"Seegers","year":"2020","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.21.11359","article-title":"Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles","volume":"93","author":"Schnell","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.7.5060-5068.1997","article-title":"Specific targeting to Cd4+ Cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins","volume":"71","author":"Johnson","year":"1997","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.8.5982-5989.1997","article-title":"High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses","volume":"71","author":"Kretzschmar","year":"1997","journal-title":"J Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1711059\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:27:54Z","timestamp":1771932474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1711059\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1711059"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1711059","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"article-number":"1711059"}}